Planung und Steuerung von Entwicklungsprojekten in der Pharmabranche

Völker, Rainer

doi:10.1007/978-3-662-07768-9_11

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2003, the major US and European pharmaceutical companies invested more than US$33 billion in R&D, at a higher R&D-to-sales ratio than virtually any other industry, including chemicals, automobiles, electronics, aerospace, and computers (PhRMA, 2004). However, while R&D processes last up to 13 years, only one of 5,000 product-ideas is launched on the market (Pfeiffer, 2000), and only one out of 10,000 substances becomes a marketable product (Völker, 2001). In addition, only three out of ten drugs that reach the market generate revenues that meet or exceed average R&D costs, and the 20 percent of products with the highest returns generate 70 percent of total returns F according to a study by Duke University economists (Reuters, 2002).…”

Section: Innovation As a Key Success Factor In The Pharmaceutical Indmentioning

confidence: 99%

Organizing Pharmaceutical Innovation: From Science‐based Knowledge Creators to Drug‐oriented Knowledge Brokers

Gassmann,

Reepmeyer

2005

Creat Innov Manage

129

View full text Add to dashboard Cite

The pharmaceutical industry is exposed to severe conditions: while a typical R&D process lasts up to 13 years, only one out of 10,000 substances becomes a marketable product. In addition, markets for pharmaceutical products tend to become more fragmented, leading to an increased risk of market failure. At the same time, R&D productivity has been deteriorating for several years. The number of new drug approvals is constantly declining, while R&D expenditures are escalating as a result of high investments in new drug discovery technologies and more complex clinical studies. As a response, pharmaceutical firms have started to focus on balancing the right size and structure of their R&D activities. This leads to several organizational trends: (1) novel management of technologies; (2) R&D internationalization; and (3) open innovation modes.

show abstract

Section: Innovation As a Key Success Factor In The Pharmaceutical Indmentioning

confidence: 99%